Nachrichten zur Biogen Inc. Aktie

Biogen Appoints Adam Keeney as Head of Corporate Development

CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam…

Legend Biotech appoints former CEO of Biogen as advisor

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Price Over Earnings Overview: Biogen

Eisai, Biogen Present Lecanemab New Analyses In Phase 3 Trial; Detailed Analyses In Phase IIb Trial

WESTON (dpa-AFX) - Drug makers Biogen Inc. (BIIB) and Japans Eisai Co., Ltd. (ESALY.PK, ESALF.PK) announced Friday new analyses from…

Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

Insiderhandel: Head of Development verkauft Aktien von Biogen im Wert von 153.394$

Singhal, Priya - Vorstand - Tag der Transaktion: 2023-03-28...…

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

Biogen Inc. (BIIB) closed at $274.01 in the latest trading session, marking a +1.39% move from the prior day....…

Biogen: BIIB080 Phase 1b Study Shows Reduction Of Tau PET Across Brain Regions

WESTON (dpa-AFX) - Biogen Inc. (BIIB) reported Phase 1b clinical data showing that the investigational antisense oligonucleotide therapy, BIIB080, reduced…

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Biogen Inc. (BIIB) closed at $269.98 in the latest trading session, marking a -0.02% move from the prior day....…

Biogen Unusual Options Activity

Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA

The FDA committee supports an accelerated approval of Biogens (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the…

Biogen Updates On FDA Advisory Committee Meeting On Tofersen For SOD1-ALS

WESTON (dpa-AFX) - Biotechnology company Biogen Inc. (BIIB) announced the outcome of the U.S. Food and Drug Administrations Peripheral and…

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States SOD1-ALS is a…

Biogen ALS drug considered not effective by FDA advisory panel

Biogen Inc. BIIB received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug…

Biogen ALS drug tofersen earns mixed voting by FDA advisory panel

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

FDA advisors reject Biogens ALS drug for rare and aggressive form of the disease

FDA advisors voted against Biogens investigational ALS drug, which could become the first to target a genetic cause of the…

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session....…

Wall Street predicts approval for another ALS drug

An FDA advisory committee is set to meet this week to discuss a drug developed by Biogen and Ionis to…

FDA staff says Biogens ALS drug may have a clinical benefit on a rare form of the disease

The FDA staff on Monday said Biogens investigational ALS drug tofersen may have a "clinical benefit" on a rare and…

Biogen Data Suggest ALS Drug Has Treatment Effect, FDA Staff Say

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...…

FDA scientists weigh potential effect of Biogen ALS drug ahead of advisory meeting

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Should You Buy Biogen Before a Big July Decision?

Biogen stock has dropped about 40% from its record high....…

Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations

Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations...…

Sangamo down post-market as Novartis, Biogen end collaborations

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Price Over Earnings Overview: Biogen

Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges

Most of Biogens (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi…

Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing Protection

CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice…

Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $262.37, moving +0.01% from the previous trading session....…

Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know

In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day....…

Biogen: Positives zu Zuranolone - Aktienanalyse

Toronto (www.aktiencheck.de) - Biogen-Aktienanalyse von RBC Capital Markets: Brian Abrahams, Analyst vom Investmenthaus RBC Capital Markets, bewertet die Aktie von Biogen…

The VA Will Pay for Leqembi. Its a Step in Right Direction for Biogen.

The biotech and its partner Eisai are seeking to get Medicare to pay for the new Alzheimer's disease therapy....…

1 Reason to Buy Biogen Stock, and 1 Reason to Sell

It could be a make or break year for the biotech....…

Biogen Appoints Chuck Triano as Head of Investor Relations

CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck…

Eisai sees Biogen-partnered Alzheimer’s therapy to bring over $7B sales in 2030

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

Biogen Inc. (BIIB) closed the most recent trading day at $263.02, moving -0.7% from the previous trading session....…

Biogen elects new board chairperson

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors

CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that the Board of…

FDA Will Weigh Full Approval for Alzheimers Drug. Why It Matters for Biogen Stock.

The drug already has accelerated approval. Full approval would open the door for Medicare to pay for the treatment for…

Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi

The FDA grants priority review to Biogen (BIIB) and Eisais sBLA seeking traditional approval of Alzheimers disease drug, Leqembi. The…

Roche-Tochter Genentech verklagt Biogen wegen Patentgebühren

Pharmabranche - Die amerikanische Roche-Tochter Genentech hat einem Bericht zufolge am Dienstag den Konkurrenten Biogen vor einem Bundesgericht in San…

Roche-Tochter Genentech verklagt Biogen wegen Patentgebühren

Die Roche-Tochter Genentech hat laut einem Bericht der Nachrichtenagentur Reuters am Dienstag den Konkurrenten Biogen vor einem Bundesgericht in San…

Genentech sues Biogen for royalties on blockbuster MS drug

...By Blake Brittain (Reuters) - Roches Genentech Inc sued Biogen......…

Biogen Says BLA For Lecanemab Gets Priority Review By NMPA In China

WESTON (dpa-AFX) - Eisai Co., Ltd. and Biogen Inc. (BIIB) Tuesday said the Biologics License Application (BLA) for lecanemab, has…

Biogen: Kursziel angehoben

New York (www.aktiencheck.de) - Rating-Update: Das Anlagevotum der Analysten von Morgan Stanley für die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN:…

Declining MS Sales for Historic Powerhouse Biogen Point to Shifting Tides in the Multiple Sclerosis Market According to Spherix Global Insights

U.S. neurologists increasingly favor Novartis MS portfolio, particularly Kesimpta EXTON, Pa., Feb. 17, 2023 /PRNewswire/ -- According to Biogens earnings…

dpa-AFX ProFeed